ETONEton Pharmaceuticals, Inc.
Price
+163%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Eton Pharmaceuticals, Inc. (ETON) reported revenue of $38M in Q2 2026 (quarter ended Jun 30, 2026), up 99% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $12M (31% of revenue). For the full year FY2025, revenue was $80M (+105% year on year) and net income −$4.6M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules.Other event · Form 8-K
- Aug 5, 2026On July 31, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a license agreement (the "Agreement") for a late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc. ("Auson") for the treatment of proliferating superficial infantile hemangiomas.Material agreement entered · Form 8-K
- Aug 4, 2026On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #34 of 41 by RyuScore